Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium

Advances in Therapy

Volumn 32, Issue 10, 2015, Pages 920-928

  Lousada, Isabelle ^a   Comenzo, Raymond L ^b   Landau, Heather ^c   Guthrie, Spencer ^d   Merlini, Giampaolo ^e  

^a Amyloidosis Research Consortium   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d Prothena Biosciences Inc   (United States)

^e UNIVERSITY OF PAVIA   (Italy)

Author keywords

Disease awareness; Early diagnosis; Patient survey; Systemic amyloidosis; Treatment

Indexed keywords

ADULT; AGED; AMYLOIDOSIS; ARTICLE; CARDIOLOGIST; CAREGIVER; CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); FAMILY; FEMALE; FOLLOW UP; GASTROENTEROLOGIST; GENERAL PRACTITIONER; HEALTH CARE ACCESS; HEALTH SURVEY; HEMATOLOGIST; HUMAN; LIGHT CHAIN AMYLOIDOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEPHROLOGIST; NEUROLOGIST; ONCOLOGIST; ORGAN TRANSPLANTATION; PHYSICIAN; QUALITY OF LIFE; STEM CELL TRANSPLANTATION; TREATMENT RESPONSE; HEALTH CARE DELIVERY; PSYCHOLOGY; QUESTIONNAIRE;

AGED; AMYLOIDOSIS; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; STEM CELL TRANSPLANTATION; SURVEYS AND QUESTIONNAIRES;

EID: 84946496097     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-015-0250-0     Document Type: Article

References (11)

1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349:583–96.
2. Sanchorawala V. Light-chain (AL) amyloidosis: diagnosis and treatment. Clin J Am Soc Nephrol. 2006;1:1331–41.
3. Merlini G, Comenzo RL, Seldin DC, Wechalekar A, Gertz MA. Immunoglobulin light chain amyloidosis. Exp Rev Gastroenterol Hepatol. 2014;7:143–56.
4. Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia. 2012;26:2317–25.
5. Merlini G, Wechalekar AD, Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood. 2013;121:5124–30.
6. Kyle RA, Linos A, Beard CM, Linke RP, Gertz MA, O’Fallon WM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood. 1991;79:1817–22.
7. National Comprehensive Cancer Network, Inc. (2015) NCCN clinical practice guidelines in oncology: systemic light chain amyloidosis. Version 1. 2015. https://www.nccn.org/store/login/login.aspx?ReturnURL=http://www.nccn.org/professionals/physician_gls/pdf/amyloidosis.pdf. Accessed 19 May 2015.
8. Wechalekar AD, Gillmore JD, Bird J, Cavenagh J, Hawkins S, Kazmi M, et al. Guidelines on the management of AL amyloidosis. Br J Haematol. 2015;168:186–206.
9. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004. Am J Hematol. 2005;79:319–28.
10. Palladini G, Hegenbart U, Milani P, Kimmich C, Foli A, Ho AD, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 2014;124:2325–32.
11. Gertz MA. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment. Am J Hematol. 2014;89:1132–40.